Plain-English translation of NCT06012734 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a combination of two medications called and in people with advanced colorectal cancer. The trial will first figure out the safest dose of to use with , then test whether this combination can shrink tumors and help patients live longer. Researchers believe that using these two medications together might work better than either one alone.
Many patients with advanced colorectal cancer stop responding to standard treatments. This medication combination targets cancer in new ways—one helps restart the immune system's cancer-fighting ability, while the other may help cancer cells become more visible to the immune system. The trial exists to see if this approach can help patients who have run out of other options.
You likely qualify if…
You likely don't qualify if…
You would receive both medications through an IV infusion every 21 days (3 weeks). is given twice per cycle (on day 1 and day 3), while is given once per cycle (on day 1). You would visit the clinic regularly for blood tests, scans to check if your tumor is shrinking, and tumor biopsies to help researchers understand how the medications are working. Treatment continues as long as the cancer doesn't grow and you're not experiencing unacceptable side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Netherlands